Syenza News — health technology assessment, market access and health economics
JNJ-6143 prostate cancer: 75% tumor response in Phase 1 trial
JNJ-6143, an investigational first-in-class oral molecule, produced a 75% tumor response rate among patients with measurable disease in a Phase 1 study. #SyenzaNews #prostatecancer #oncology
Recent Posts
Claudin 18.2 antibody-drug conjugate prolongs survival in gastro-oesophageal cancer
Oct 26
Obesity drug reimbursement in Portugal: new SNS terms
Oct 26
Antiretroviral Tender Awards Declared Invalid by Pretoria Court
Oct 26
Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%
Oct 23
FDA Launches Neuroscience Medical Product Development Program
Oct 23Syenza's Top Picks
EMA Expert Panel Consultation for Medical Devices Adds an Orphan Pathway
Oct 14, 2026
EMA Draft Reflection Paper Sets Rules for Confirmatory Platform Trials
Oct 19, 2026
Reinforcement learning rTMS for depression treatment
Oct 19, 2026
AI operating room scheduling: LLM agent teams reach feasible plans
Oct 16, 2026
Most favored nation drug pricing: why US patient groups push back
Oct 16, 2026
FDA Rare Disease Framework Initiative Would Tailor Review to Small Populations
Oct 15, 2026
Latest News
Artificial Intelligence And Machine Learning
Clinical AI governance framework guides AI tool evaluation
A new npj Digital Medicine article in press from SCPMG proposes the C-TACT clinical AI governance framework, with weighted lifecycle scorecards and its limits stated.
Clinical Practice
Palbociclib Maintenance in HER2-Positive Breast Cancer: EMA Withdrawal
Pfizer has withdrawn its EU application for palbociclib in HER2-positive breast cancer. EMA questioned the open-label PATINA endpoint.
Clinical Practice
Health Economists in Clinical Trials: Why Early Engagement Matters
Health economists in clinical trials are most useful when they join early, explain their methods in plain language and plan for the data they will need. That was the central message of a webinar brought together by University College London and the Global Health Network at the University of Oxford. A professor of health policy and systems management in Uganda moderated three panelists with trial experience across Africa and Asia. Why trials need economic questions The moderator framed the session […]
Big Data Analysis
New Drug Launch Prices Stay High While Patients Wait for Access
New drug launch prices are still high. ICER’s 2026 Launch Price and Access Report finds the median net price for 2025 approvals was about $257,000, and only about one in three new prescriptions was filled within 30 days. #SyenzaNews #MarketAccess #HEOR
Clinical Practice
CagriSema Weight Loss in Women: Menopause Stages in REDEFINE 1
Two post hoc REDEFINE 1 analyses show CagriSema weight loss in women held across premenopausal, perimenopausal and postmenopausal stages. #SyenzaNews #obesity #MarketAccess
Health Policy Free account
Medicaid Provider Taxes Raise Private Insurance Premiums, ASPE Finds
ASPE finds Medicaid hospital provider taxes raised employer premiums 1.5 to 1.7 percent, and the 2025 WFTC law is projected to cut them further.
Alzheimer's Disease
Biomarker laboratory in Portugal opens at University of Porto
A new biomarker laboratory in Portugal opens on 21 October at the University of Porto, funded with 2.1 million euros from the PRR. #SyenzaNews #biomarkers #precisionmedicine
Clinical Practice
Emvistegrast in ulcerative colitis hits Phase 2 primary endpoint
Gilead’s once-daily oral emvistegrast met the primary endpoint in Phase 2 SWIFT ulcerative colitis data, with 66% clinical response at Week 12 versus 37% on placebo. #SyenzaNews #biotechnology #MarketAccess
Clinical Practice
Jemperli rectal cancer approval may let some patients skip standard treatment
FDA grants accelerated approval for Jemperli in locally advanced rectal cancer, based on interim AZUR-1 results. #SyenzaNews #oncology #MarketAccess
Clinical Practice
Adverse reaction reports in Portugal rise with GLP-1 use
Infarmed has logged 695 suspected adverse reactions to GLP-1 drugs in Portugal since 2024, most linked to Mounjaro.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.
